drugset / Trial / NCT06866080
A Study of LCAR-AIO in Subjects With Relapsed/Refractory Autoimmune Diseases
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label, dose-exploration and expansion clinical study of LCAR-AIO in adult subjects with relapsed/refractory autoimmune diseases.
Timeline
- Start
- 2025-06-17
- Primary completion
- 2025-06-17
- Completion
- 2025-06-17
Outcome
Outcome not reported
Stopped: “Discontinue further development of LCAR-AIO program”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LCAR-AIO | Cell therapy | — | Other |
Indications
No indication recorded.